Navigation Links
Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Date:3/6/2008

CALGARY, March 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today reported its financial results for the year ended December 31, 2007.

"2007 was our most productive year to date, marking a significant expansion of the Company's clinical trial program for REOLYSIN(R) with Phase II studies and combination drug therapy studies being expanded and initiated," said Dr. Brad Thompson, President and CEO of Oncolytics. "This activity was supported by further advances in our preclinical development program, manufacturing, and intellectual property."

Selected Highlights:

Clinical Trial Results Presented

--------------------------------

- Final results from our Phase I U.K. systemic administration trial, and

our U.S. Phase I systemic administration trial at ASCO;

- Positive interim results from our U.K. Phase Ia/Ib combination

REOLYSIN(R) and radiation trial;

Clinical Trial Progress

-----------------------

- Commenced patient enrolment in three combination REOLYSIN(R) and

chemotherapy trials in the U.K.;

- Commenced patient enrolment in a U.S. Phase II trial for patients with

various sarcomas that have metastasized to the lung;

- U.S. National Cancer Institute (NCI) filed a protocol with the U.S.

Food and Drug Administration (FDA) to conduct a Phase II melanoma

trial with REOLYSIN(R);

- Approval to begin a Phase I combination REOLYSIN(R) and

cyclophosphamide trial in the U.K.;

- In January 2008, the NCI filed a protocol with the U.S. FDA to conduct

a Phase I/II ovarian, peritoneal and fallopian tube cancer trial;

- In January 2008, met the criteria to expand to full enrolment of 52

patients in our U.S. Phase II sarcoma trial;

Manufacturing

-------------

- Completed scale up of our manufacturing process to
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
3. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
4. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
5. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
6. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
8. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
9. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
10. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
11. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has filed its Annual Report on Form ... filed Form 20-F includes audited financial statements for the ... can be accessed by visiting the U.S. Securities and ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace , ... the interpretation and analysis of genomic and other ... has joined the company as Vice President ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners ... integrate, interpret, analyze and explore complex sets of ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... 2 to 3 children in 100 are born with a ... but in 80% of the cases scientists do not know ... Katholieke Universiteit Leuven, in collaboration with an Australian research team, ... mental retardation is caused by a twofold production of two ...
... Jan. 24 Cardica, Inc.,(Nasdaq: CRDC ) ... fiscal 2008 second quarter and six months ended ... excellent commercial progress, with over 1,000,C-Port systems shipped ... an expanding,product line designed to enable minimally-invasive cardiac ...
... Defined Structure Synthesized,in the Lab, Team Completes Second ... ROCKVILLE, Md., Jan. 24 A team of 17,researchers ... the largest,man-made DNA structure by synthesizing and assembling the ... This work, published,online today in the journal Science by ...
Cached Biology Technology:Discovery of new cause of mental retardation simplifies search for treatments 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7Venter Institute Scientists Create First Synthetic Bacterial Genome 2Venter Institute Scientists Create First Synthetic Bacterial Genome 3Venter Institute Scientists Create First Synthetic Bacterial Genome 4Venter Institute Scientists Create First Synthetic Bacterial Genome 5Venter Institute Scientists Create First Synthetic Bacterial Genome 6
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... plants supplement the meager diet available from the nutrient-poor ... insects and other small arthropods. Pitcher plants of the ... a simple passive trap but in a paper in ... a biologist and a physicist from the CNRS, working ...
... University center that aims to improve crop production by ... of continued and expanded support from the Monsanto Company, ... will fund student exchanges and a series of plant ... for Plant Molecular Genetics and Agrobiotechnology , a multidisciplinary ...
... emissions from using coal are set to double by 2030, ... global climate change. In view of the essential role of ... where coal is used. The British Geological Survey ... Phase 1 study in Beijing, China today. The aim of this ...
Cached Biology News:Carnivorous plants use pitchers of 'slimy saliva' to catch their prey 2Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center 2UK scientists lead China closer to carbon capture and storage 2
... The TargeTron(TM) Gene Knockout System provides optimized ... specific disruption of bacterial genes by insertion ... the retrohoming ability of group II introns ... re-target the TargeTron group II intron for ...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
... antibody raised against a partial recombinant IFNA2. ... partial recombinant protein is produced in E. coli. ... IU/ mg. OMIM: 147562, ... Lot Number: MM951100564 MA Code: ...
Biology Products: